Quantitative EEG amplitude across REM sleep periods in depression: preliminary report

Marcus P. Liscombe, BA; Robert F. Hoffmann, PhD; Madhukar H. Trivedi, MD; Marc K. Parker, BA; A. John Rush, MD; Roseanne Armitage, PhD

Objective: To determine if there are significant differences in the temporal organization of rapid eye movement (REM) sleep microarchitecture between healthy controls and outpatients with major depressive disorder (MDD). Methods: Forty age-matched subjects, 20 men and 20 women, half with MDD, were selected from an archive of sleep electroencephalography (EEG) data collected under identical conditions. Each participant spent 2 consecutive nights in the Sleep Study Unit of the University of Texas Southwestern Medical Center at Dallas, the first of which served as adaptation. The average amplitude in each of 5 conventional EEG frequency bands was computed for each REM period across the second night. Data were then coded for group and sex. Results: Aside from REM latency, none of the key sleep macroarchitectural variables differentiated MDD patients from controls. REM latency was longest in men with MDD. Sleep microarchitecture, however, did show a number of between-group differences. In general, slower frequencies declined across REM periods, with a significant REM period effect for delta, theta and alpha amplitude. Group × sex interactions were also obtained for theta and alpha. Beta activity showed a unique temporal profile in each group, supported by a significant REM period × group × sex interaction. In addition, the temporal change in theta amplitude across REM periods was most striking in women with MDD. Conclusions: This study suggests that, like during non-REM sleep, EEG amplitude shows a systematic temporal change over successive REM sleep periods and also shows elements that are both disease- and sex-dependent.

Correspondence to: Dr. Roseanne Armitage, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas TX 75390-9070; fax 214 648-7359; Roseanne.Armitage@UTSouthwestern.edu
Introduction

There is ample evidence that the timing or distribution of rapid eye movement (REM) sleep and non-REM sleep stages are disrupted in those with major depressive disorders (MDD). Furthermore, the micro-architecture of sleep based on quantitative electroencephalographic (EEG) analysis shows a number of abnormalities in patients with MDD. Elevated fast-frequency, decreased slow-wave activity and dysregulation of ultradian sleep EEG rhythms have all been reported as characteristic of those with MDD. Recent work also indicates that it is primarily men with MDD who show an aberrant time course of slow-wave activity in non-REM sleep, whereas women with MDD are more likely to show ultradian rhythm abnormalities.

Most quantitative sleep EEG studies in MDD, however, have focused on non-REM sleep. To date, it is not clear whether these sex differences are also evident in REM sleep. Since women are at twice the lifetime risk of men for developing depression and since that risk occurs mainly during the reproductive years, it is reasonable to assume that there are biological factors that contribute to risk of depression. Sleep EEG studies provide some of the strongest support for the biological basis of depression and certainly present an ideal opportunity to investigate why women are at greater risk. Unfortunately, only a handful of sleep studies have assessed potential sex differences in depression or in healthy controls.

The purpose of this preliminary report was to investigate potential sex differences in the temporal organization of REM sleep in depressed individuals and in healthy controls. It was expected that sex differences in the group with MDD would be larger than those observed in healthy adults.

Methods

The subjects were divided into groups on the basis of clinical diagnosis and sex. All participants were right-handed. The normal control (NC) group consisted of 10 men, 25–40 years of age (mean 30.8 [standard deviation (SD) 6.0] yr) and 10 women, 22–40 years of age (mean 30.4 [SD 5.0] yr). The MDD group consisted of 10 men, 22–40 years of age (mean 30.1 [SD 5.3] yr) and 10 women, 22–39 years of age (mean 30.6 [SD 5.4] yr). Outpatients who met criteria for nonpsychotic major depression (single or recurrent) but were otherwise physically healthy comprised the MDD group. Diagnoses were based on the Structured Clinical Interview for DSM-III-R (SCID) or DSM-IV. Patients were mild-to-moderately ill, with an average score of 21.4 (SD 3.9) on the 17-item Hamilton rating scale for depression (minimum 17). They were also medication free for a minimum of 2 weeks before the study (4 weeks for monoamine oxidase inhibitors, 6 weeks for fluoxetine). Other current Axis I disorders, current general medical conditions or substance abuse 12 months before baseline excluded subjects. All control subjects were medically fit and had no personal family history of Axis I disorders or substance abuse based on the SCID-NP (non-patient version). Independent sleep disorders such as narcolepsy, sleep apnea and bruxism were ruled out by medical history or polysomnogram. Shift work was also exclusionary.

Procedure

Each participant spent 2 consecutive nights in the University of Texas Southwestern Medical Center Sleep Study Unit, the first of which served as laboratory night. The second night was used for REM sleep EEG in depression

Vol. 27, No. 1, 2002 Journal of Psychiatry & Neuroscience
adaptation. All participants maintained regular bed- and rise-times for 5 days before the study, and this was verified by home diary. This habitual sleep schedule was also followed in the laboratory. Any subject with more than a half-hour of deviation in sleep schedule during the 5 days was excluded from the study. Subjects entered the laboratory for electrode application approximately 1.5 hours before the scheduled bedtime.

The electrode montage included left (C3) and right (C4) central EEG, left and right electro-oculograms (EOG) recorded from the upper and lower canthi, and a bipolar, chin–cheek electromyogram (EMG). The first night also served as an additional screening for independent sleep disorders (e.g., apnea, bruxism and periodic limb movements) and included leg leads, chest and abdomen respiration bands and a nasal–oral thermistor in the electrode montage. EEG electrodes were referenced to the earlobes connected to a 10-kΩ resistor to minimize nonhomogeneous current flow and potential artifactual hemispheric asymmetries, as is standard in our laboratory. EEG was transduced by GRASS P511 A/C amplifiers set at a sensitivity of 5 (50 µV, 0.5-s calibration), corresponding to a gain of 50,000. The half-amp low- and high-bandpass filters were set at 0.3 Hz and 30 Hz, respectively. A 60-Hz notch filter attenuated electrical noise. Signals were digitized online at 250 Hz (62.5 Hz for EOG and EMG) through a 16-bit MICROSTAR analogue-to-digital polygraph system, which was designed and validated in-house.

Signal processing

Period amplitude analysis (PAA) was used to quantify EEG activity and has been described in detail elsewhere. Briefly, PAA evaluates wave incidence and amplitude 250 times/s and accumulates over 30 s in each of delta (0.5 Hz to below 4 Hz), theta (4 Hz to below 8 Hz), alpha (8 Hz to below 12 Hz), sigma (12 Hz to below 16 Hz) and beta (16 Hz to below 32 Hz) frequency bands. For the purpose of this report, EEG amplitude (in µV²) in each frequency band was averaged across C3 and C4 electrodes.

Sleep records were scored from C3 electrodes in 30-s epochs, according to standard criteria, by research personnel trained at better than 90% agreement on an epoch-by-epoch basis. Scorers were blind to the clinical status and sex of study participants. Note that both computer and human evaluation of sleep EEG were based on identical 30-s epochs. All records were inspected visually, and epochs containing movement, breathing or muscle artifact or recording difficulties were excluded from the analysis. An average of 7.8 (SD 2.1) epochs were excluded, resulting in the loss of less than 5 minutes of EEG data over the 7- to 8-hour recording period, in any individual record.

Data analysis

The REM periods were defined by 3 rules. First, a minimum 3-minute duration was required to begin a REM period. At least 10 consecutive epochs of non-REM or awake were required to terminate a single REM period. This criterion was chosen to be comparable with non-REM period definitions in previous work. Second, subsequent REM periods had to be at least 60 epochs (i.e., 30 min) after the preceding REM period, in accordance with the rules of Rechtschaffen and Kales. Finally, the last REM period had to end either in accordance with the rules above or terminated by the morning awakening. After each REM period was defined, amplitude and incidence measures were summed and averaged for each subject. Note that because intervening wake, movement and non-REM epochs do occur within each REM period, all amplitude measures were based only on the REM epochs (i.e., net REM) within each REM period. Thus, the definition dictated that a minimum of 75,000 samples (250 Hz × 30 s × 5 min) would be available in which amplitude could be evaluated in each REM period. For statistical purposes, only the first 3 REM periods were included for analysis because only some of the participants had 4 or more complete REM periods for the night.

Data were then coded for group (MDD or NC) and sex. Repeated-measures analyses of variance (ANOВS) were computed, treating REM period as a 3-level repeated measure and group and sex as between-group variables. Between-group interactions were tested first, followed by between-group main effects if no interaction was evident. Least-squares multiple comparisons tested differences between individual means at an experiment-wise p < 0.05, to protect against possible type I errors.

Results

Although overall sleep microarchitecture was more disturbed in the MDD group, none of the group main effects reached statistical significance (p > 0.05). Group
× sex interactions were obtained for REM latency ($p < 0.04$), and multiple comparisons confirmed longer REM latency in men with MDD than in women with MDD and NC men ($p < 0.02$). As seen in Table 1, women with MDD had more slow-wave (stage 3 and 4) sleep, but this difference only approached significance ($p < 0.08$). Further, the latencies and durations of individual REM periods did not differ between groups. As a result, no further analyses were conducted on these measures.

Sleep microarchitecture, however, did show a number of between-group differences. The means and SDs for sigma, alpha and delta amplitude measures are shown in Table 2. Between-group differences in theta

### Table 1: Sleep stage variables for patients with major depressive disorder and controls

<table>
<thead>
<tr>
<th>Sleep stage variable</th>
<th>Male controls, n = 10</th>
<th>Female controls, n = 10</th>
<th>Men with MDD, n = 10</th>
<th>Women with MDD, n = 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sleep period, min</td>
<td>410.6 (38.7)</td>
<td>426.0 (36.5)</td>
<td>444.9 (56.7)</td>
<td>418.6 (39.7)</td>
</tr>
<tr>
<td>Sleep latency, min</td>
<td>18.7 (21.9)</td>
<td>8.2 (6.2)</td>
<td>13.3 (8.7)</td>
<td>16.8 (9.5)</td>
</tr>
<tr>
<td>Sleep efficiency, TSP/TIB</td>
<td>90.7 (4.4)</td>
<td>97.3 (2.6)</td>
<td>96.1 (3.3)</td>
<td>89.7 (2.4)</td>
</tr>
<tr>
<td>% stage 1 in TSP</td>
<td>15.8 (7.9)</td>
<td>13.9 (4.9)</td>
<td>18.2 (5.4)</td>
<td>14.8 (7.7)</td>
</tr>
<tr>
<td>% stage 2 in TSP</td>
<td>55.1 (6.8)</td>
<td>56.6 (5.3)</td>
<td>53.4 (8.1)</td>
<td>49.8 (9.5)</td>
</tr>
<tr>
<td>% stages 3 and 4 in TSP</td>
<td>5.0 (5.1)</td>
<td>4.8 (5.6)</td>
<td>3.7 (5.2)</td>
<td>10.2 (7.0)</td>
</tr>
<tr>
<td>% REM in TSP</td>
<td>18.8 (4.4)</td>
<td>20.5 (3.7)</td>
<td>18.6 (4.8)</td>
<td>18.6 (6.3)</td>
</tr>
<tr>
<td>REM density</td>
<td>2.6 (0.7)</td>
<td>2.3 (0.7)</td>
<td>2.6 (0.7)</td>
<td>2.2 (0.6)</td>
</tr>
</tbody>
</table>

Note: SD = standard deviation, MDD = major depressive disorder, TSP = total sleep period, TIB = time in bed, REM = rapid eye movement.

### Table 2: REM period characteristics by sex and group

<table>
<thead>
<tr>
<th>Period, variable</th>
<th>Male controls</th>
<th>Female controls</th>
<th>Men with MDD</th>
<th>Women with MDD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latency, min</td>
<td>64.4 (11.2)</td>
<td>78.0 (24.8)</td>
<td>89.7 (28.1)</td>
<td>66.6 (10.9)</td>
</tr>
<tr>
<td>Duration, min</td>
<td>14.5 (9.1)</td>
<td>12.6 (8.9)</td>
<td>24.5 (18.7)</td>
<td>16.4 (8.3)</td>
</tr>
<tr>
<td>Net REM, min</td>
<td>10.1 (5.8)</td>
<td>11.0 (8.7)</td>
<td>18.5 (15.0)</td>
<td>11.5 (3.5)</td>
</tr>
<tr>
<td>Excluded, min</td>
<td>4.4 (5.3)</td>
<td>1.6 (2.0)</td>
<td>6.0 (4.2)</td>
<td>4.9 (7.5)</td>
</tr>
<tr>
<td>Sigma, $\mu V^2$</td>
<td>17.1 (6.4)</td>
<td>16.8 (6.4)</td>
<td>14.7 (4.3)</td>
<td>17.9 (6.3)</td>
</tr>
<tr>
<td>Alpha, $\mu V^2$</td>
<td>37.4 (13.5)</td>
<td>32.6 (12.6)</td>
<td>25.5 (8.6)</td>
<td>38.7 (8.1)</td>
</tr>
<tr>
<td>Delta, $\mu V^2$</td>
<td>307.9 (57.5)</td>
<td>368.2 (102.9)</td>
<td>275.4 (88.0)</td>
<td>341.6 (71.6)</td>
</tr>
<tr>
<td>Latency, min</td>
<td>153.1 (27.3)</td>
<td>159.2 (46.7)</td>
<td>192.1 (53.7)</td>
<td>156.4 (17.2)</td>
</tr>
<tr>
<td>Duration, min</td>
<td>21.0 (8.3)</td>
<td>27.4 (9.2)</td>
<td>26.1 (8.0)</td>
<td>26.2 (13.2)</td>
</tr>
<tr>
<td>Net REM, min</td>
<td>15.0 (8.7)</td>
<td>18.2 (4.9)</td>
<td>19.3 (6.8)</td>
<td>20.3 (10.9)</td>
</tr>
<tr>
<td>Excluded, min</td>
<td>6.0 (2.5)</td>
<td>9.2 (7.3)</td>
<td>6.8 (7.6)</td>
<td>5.9 (6.5)</td>
</tr>
<tr>
<td>Sigma, $\mu V^2$</td>
<td>14.5 (5.2)</td>
<td>14.8 (4.4)</td>
<td>12.7 (5.2)</td>
<td>16.7 (4.8)</td>
</tr>
<tr>
<td>Alpha, $\mu V^2$</td>
<td>31.6 (10.7)</td>
<td>29.6 (10.8)</td>
<td>22.9 (8.6)</td>
<td>35.4 (6.7)</td>
</tr>
<tr>
<td>Delta, $\mu V^2$</td>
<td>306.4 (73.7)</td>
<td>309.8 (167)</td>
<td>261.4 (80.6)</td>
<td>320.9 (53.2)</td>
</tr>
</tbody>
</table>

* Note that the duration of each REM period is the net REM plus the minutes of other stages that were excluded from calculation of average power (i.e., Duration = Net REM + Excluded).
and beta amplitude are illustrated in Fig. 1 and Fig. 2, respectively. A significant REM period repeated-measures effect was evident for delta amplitude \( p < 0.01 \). Significant REM period and group × sex effects were also obtained for theta amplitude \( p < 0.0003 \) and \( p < 0.02 \), respectively) and alpha amplitude \( p < 0.002 \) and \( p < 0.005 \), respectively). Beta amplitude showed a group × sex × REM period interaction \( p < 0.04 \).

In general, EEG amplitude in slower frequencies showed a decline across successive REM periods. Women in both MDD and NC groups had higher overall delta amplitude than their male counterparts, confirmed by multiple comparisons \( p < 0.05 \). This effect was restricted to the first REM period. Moreover, the repeated-measure effect (i.e., the decline in delta over REM period) was larger than the sex difference.

With regard to alpha amplitude, men with MDD had lower alpha amplitude than MDD women in all 3 REM periods \( p < 0.05 \). Multiple comparisons also confirmed higher theta amplitude in the women with MDD compared with all other groups for each REM period \( p < 0.01 \). Women with MDD also showed a stronger decline over the REM sleep periods.

By contrast, each group showed distinct and different temporal changes in fast-frequency activity. Beta amplitude was higher in MDD groups than in the corresponding NC groups, as expected from previous work. However, MDD men had higher beta amplitude than MDD women in the first REM period, an effect that reversed by the second REM period, with no sex difference in the third REM period. Moreover, sex differences in the NC group were in the opposite direction. None of the between-group multiple comparisons were significant, indicating that is the pattern of change across REM periods (i.e., the repeated measure) that differentiated the groups and produced the significant group × sex interaction (Fig. 2).

**Discussion**

The results of this study suggest that, like non-REM sleep, EEG amplitude shows a systematic temporal change over successive REM sleep periods, particularly for delta amplitude. Theta amplitude also declined over REM periods, but the effects were most pronounced in women with MDD. The trends, however, appear less systematic in faster frequency bands with a unique temporal profile in each group. Temporal changes in beta and theta amplitude also showed stronger sex differences in the MDD group than in the NC group. These findings are in general agreement with our previous studies identifying robust group × sex interactions in non-REM sleep EEG\(^{21,39}\) and provide further evidence that the pathophysiology of depression differs in men and women.

The strong results reported here are remarkably concordant with the results and conclusions of Antonijevic et al.\(^{20,21}\) In fact, both sleep macro- and microarchitecture data from the 2 research groups are quite similar. In addition, Antonijevic et al.\(^{21}\) have suggested a sexual
dimorphism in neuroendocrine function that is disease-dependent. It may very well contribute to the sex differences in sleep and depression between men and women. Further support for this notion has come from Rubin and colleagues, who have demonstrated sexual dimorphism in cholinergic neurotransmitter function and hypothalamic-pituitary-adrenal axis activity in depression. Moreover, recent reviews have highlighted a number of sex differences in sleep and mood regulation that are related to gonadal hormone regulation. These biological factors may contribute to the sex difference observed here and in other studies.

Our results also suggest a dynamic temporal organization of EEG activity in REM sleep like that demonstrated in non-REM sleep in numerous studies of healthy individuals. A caveat may be necessary, however, since the temporal organization is influenced by group and sex.

There were some surprising findings in this study. First, enhanced theta amplitude might be expected to occur in longer duration, more phasic REM periods. Thus, higher theta amplitude would be expected in the latter REM periods of the night. By contrast, these data show a decline in theta amplitude over REM sleep in all groups. The meaning of such an outcome is not clear, although Corsi-Cabrera et al suggest that theta oscillations are under the same gonadal influence as delta and, therefore, should mirror the temporal characteristics of the latter.

Investigating the temporal organization of sleep EEG across successive REM periods may provide a sensitive means of discriminating between depressed and healthy individuals and between the sexes. It remains to be demonstrated, nonetheless, whether temporal organization of EEG microarchitecture in REM sleep falls under homeostatic regulation and shows the same response to sleep deprivation and extending prior wakefulness as slow-wave activity in non-REM sleep. Certainly, there is some evidence that this may be the case in healthy individuals. Our future work will evaluate this possibility in individuals with MDD. If the findings of this preliminary report are confirmed, it suggests that the temporal dynamics of both REM and non-REM sleep EEG are both disease- and sex-dependent.

Acknowledgements: We thank Kenneth Z. Althusher, MD, former Chair, for administrative support, the staff of the Sleep Study Unit, Darwynn D. Cole, Supervisor, Irma Aguilar, PhD, and Kimberly Yonkers, MD, for assistance in recruiting and evaluating patients and clinical follow-up.

Supported in part by the Sarah M. and Charles E. Seay Center for Brain and Applied Research in Psychiatric Illness, and NIMH MH46886.

Competing interests: None declared.

References
Health publication no 204.


Canadian College of Neuropsychopharmacology
Collège canadien de neuropsychopharmacologie

2001 Award Winners

Heinz Lehmann Award

Dr. Franco Vaccarino is the recipient of the 2001 Canadian College of Neuropsychopharmacology (CCNP) Heinz Lehmann Award. Dr. Vaccarino is currently a professor in the Departments of Psychiatry and Psychology at the University of Toronto and vice president of research at the Centre for Addiction and Mental Health. This award is designed to recognize outstanding research achievements by Canadian scientists in the field of neuropsychopharmacology. The award, donated by Hoffmann-La Roche Limited, consists of $5000 and an engraved plaque. Congratulations to Dr. Vaccarino!

Presentation: CCK modulation of mesolimbic DA function: a model for the opposing effects of stress on motivated behaviour

Jock Cleghorn Award

Mr. Steven Szabo is the recipient of the 2001 CCNP Jock Cleghorn Prize. Mr. Szabo is doing research training in the Department of Psychiatry, University of Florida in Gainesville, Fla. This award is designed to recognize the best poster presentation by a research trainee at the CCNP Annual Meeting. The award, donated by the CCNP, consists of $500. Congratulations to Mr. Szabo!

Presentation: Serotonin receptor effects on noradrenaline neuron firing are mediated through excitatory amino acid and GABA-A receptors

Innovations in Neuropsychopharmacology Award

Dr. Harold A. Robertson is the recipient of the 2001 CCNP Innovations in Neuropsychopharmacology Award. Dr. Robertson is currently professor and head of the Department of Pharmacology, Faculty of Medicine, Dalhousie University in Halifax. This award is designed to recognize outstanding research innovations in the basic or clinical fields of neuropsychopharmacology. The award, donated by Pfizer Canada Inc., consists of $5000 and an engraved plaque. Congratulations to Dr. Robertson!

Presentation: The genome and the brain: towards a neurobiology of psychiatric disorders

Young Investigator Award

Dr. Ridha Joober is the recipient of the 2001 CCNP Young Investigator Award. Dr. Joober is currently an assistant professor in the Department of Psychiatry and associate member in the Department of Neurology and Neurosurgery at McGill University. The award, donated by Bristol-Myers Squibb Company, consists of a $2500 bursary plus a $2000 research grant and an engraved plaque. Congratulations to Dr. Joober!

Presentation: Genetics of schizophrenia: combining animal models and clinical studies